MAFTEST® analyses of the NSABP-B34 and AZURE landmark clinical trials confirmed clinical utility of the MAFTEST® for selection of early-stage breast cancer patients that benefit from adjuvant clodronate treatment.
Reduces the risk of death at 5 and 10 years by 26% and 23% respectively.
Identifies almost twice as many patients able to benefit from the intervention than are selected using current clinical guidelines.
Data published in Annals of Oncology, (33), SUPPLEMENT 3, S152, 2022.
Inbiomotion SL, a company developing a unique single-gene-based biomarker for the personalized adjuvant treatment of early-stage (stage I-III) breast cancer patients, announces the results of comparing the clinical efficacy of implementing the proprietary MAFTEST® for selection of patients for adjuvant bisphosphonates therapy with current clinical guidance. The results were presented at the ESMO 2022 Breast Cancer Symposium.